Drug Pipeline

BET Bromodomain Inhibitor ZEN-3694 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
10
Active Studies
9
Recruiting
3
Top Sponsors
6
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-12 NCT05950464
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the…
date change Primary completion pushed: 2026-04-30 -> 2027-06-30
2026-06-12 NCT05950464
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the…
date change Completion pushed: 2026-04-30 -> 2027-06-30
2026-06-12 NCT05372640
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694…
date change Primary completion pushed: 2026-06-01 -> 2027-06-07
2026-06-12 NCT05372640
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694…
date change Completion pushed: 2026-06-01 -> 2027-06-07
2026-06-12 NCT05803382
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy…
date change Primary completion pushed: 2026-06-30 -> 2027-06-30
2026-06-12 NCT05803382
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy…
date change Completion pushed: 2026-06-30 -> 2027-06-30
Active Studies by Phase
Phase 2
3
Phase 1/2
3
Phase 1
4
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT05607108 A Study of ZEN003694 in People With Squamous Cell Lung Cancer Squamous Cell Lung Cancer Recruiting
NCT04986423 ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic… Metastatic Castration-Resistant Prostate Cancer Recruiting
NCT05327010 Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in… Advanced Malignant Solid Neoplasm Recruiting
Phase 1/2
NCT05053971 Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and… Advanced Malignant Solid Neoplasm Recruiting
NCT05019716 Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to… Advanced NUT Carcinoma Recruiting
NCT04145375 Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While… mCRPC Enrolling by Invitation
Phase 1
NCT05422794 Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor… Anatomic Stage III Breast Cancer AJCC v8 Recruiting
NCT05372640 Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694… Anatomic Stage III Breast Cancer AJCC v8 Recruiting
NCT05803382 Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy… Metastatic Colorectal Carcinoma Recruiting
NCT05950464 Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the… Recurrent Endometrial Carcinoma Recruiting
Sponsors Running BET Bromodomain Inhibitor ZEN-3694 Trials
Disease Areas
Get alerts when BET Bromodomain Inhibitor ZEN-3694 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free